Navigation Links
SomaLogic and Ambergen announce agreement for commercial applications of photocleavable biotin
Date:11/29/2011

SomaLogic, Inc. and AmberGen, Inc. announced today that they have entered into a licensing agreement whereby AmberGen will provide its proprietary photocleavable biotin reagent for the commercial use of SomaLogic's SOMAscanTM technology platform.

The biggest constraint on successful development of a high-throughput proteomic quantitation platform is achieving sufficient sensitivity. SomaLogic's innovative SOMAmer (Slow Off-rate Modified Aptamer) protein-capture reagents and their multiplex SOMAscan technology break through this limitation.

AmberGen has developed a range of novel molecules and compounds with photocleavable linkers, including a 5-prime photocleavable biotin, a light-activated biomolecule that it has licensed to SomaLogic. "AmberGen's photocleavable biotin element provides an efficient way to detect and measure the bound proteins as part of our SOMAscan platform" said Nick Saccomano, Ph.D., Chief Technology Officer at SomaLogic.

The SOMAscan technology platform utilizes SOMAmers to accurately screen dozens of patient samples simultaneously, allowing quantification of many specific proteins in a multiplexed, high-throughput manner. SomaLogic has thus far validated SOMAmers to a broad array of over 1000 different protein targets for use in biomarker discovery, diagnostics, and drug discovery and development.

"We look forward to exploring new applications for our photocleavable technologies with SomaLogic, as we continue to support their existing and emerging SOMAmer reagents," stated Christopher Sears, Ph.D., Chief Scientific Officer of AmberGen. "With both companies' commitment to developing tools for personalized medicine, there are ample opportunities for further collaboration."


'/>"/>

Contact: Fintan Steele, Ph.D.
fsteele@somalogic.com
617-816-9834
SomaLogic, Inc.
Source:Eurekalert

Page: 1

Related biology news :

1. SomaLogic announces agreement with leading global pharma company to accelerate R&D
2. SomaLogic and New England Biolabs announce agreement to use SOMAmers for multiple PCR products
3. SomaLogic researchers describe revolutionary new approach to protein analysis and application to early diagnosis of lung cancer
4. EpiGen announces collaboration with Nestlé
5. Minister announces UK-India collaboration on bioenergy
6. BGI announces collaborative research agreements with Oregon State University
7. NIH TRND program announces next round of drug development projects
8. DigitalPersona Announces FingerJet OEM Fingerprint Recognition Software for Biometric Device Manufacturers and Solution Providers
9. BGI announces collaboration with Johns Hopkins University on synthetic yeast project
10. Scripps Health/the Medicines Company announce late breaking BRIDGE trial results presented at TCT
11. Childrens Hospital of Philadelphia and BGI announce partnership and new Joint Genome Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, ... Infrastructure, Support & Other Service  The latest ... comprehensive analysis of the global Border Security market ... of $17.98 billion in 2016. Now: In ... in software and hardware technologies for advanced video surveillance. ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... 23, 2016 , ... In a new case report published today in STEM ... who developed lymphedema after being treated for breast cancer benefitted from an injection of ... dealing with this debilitating, frequent side effect of cancer treatment. , Lymphedema ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
Breaking Biology Technology: